RPL24A Antibody

What is the RPL24 protein and why is it targeted in research?

RPL24 (ribosomal protein L24) is an essential component of the mammalian ribosome involved in protein synthesis. This protein has a calculated molecular weight of 18 kDa, though it typically appears at 21-23 kDa in experimental conditions . Research interest in RPL24 has intensified due to its emerging roles beyond protein synthesis, particularly in cell cycle regulation and cancer development. Antibodies targeting RPL24 allow researchers to study its expression, localization, and interactions in various physiological and pathological contexts. Recent studies have revealed that RPL24 expression levels change during cancer progression and treatment response, making it a valuable research target for understanding disease mechanisms .

Which applications can RPL24 antibody be reliably used for?

RPL24 antibody has been validated across multiple experimental techniques with specific dilution requirements:

For optimal results, researchers should perform antibody titration in each specific experimental system . The antibody has been successfully used in at least 11 published Western blot studies, 3 IHC studies, 4 IF studies, and has applications in RIP and ELISA techniques as documented in published literature .

How should RPL24 antibody be stored and handled to maintain reactivity?

For maximum antibody performance, store RPL24 antibody at -20°C where it remains stable for one year after shipment. The antibody is typically provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Unlike some other antibodies, aliquoting is unnecessary for -20°C storage with this formulation. When working with smaller volumes (20μl), note that these may contain 0.1% BSA which can affect certain applications . Before each use, allow the antibody to equilibrate to room temperature and mix gently to ensure homogeneity without introducing bubbles that might interfere with pipetting accuracy.

How can I determine the optimal RPL24 antibody concentration for previously untested cell lines?

When working with a new cell line, a systematic titration approach is recommended. Begin with a pilot experiment using a dilution series spanning the manufacturer's recommended range (1:5000-1:50000 for WB, 1:50-1:500 for IHC) . For Western blots, prepare identical membranes with your samples and incubate with different antibody dilutions (e.g., 1:5000, 1:10000, 1:25000, 1:50000).

Evaluate results based on:

• Signal-to-noise ratio

• Band specificity at the expected molecular weight (21-23 kDa for RPL24)

• Background levels

For immunostaining applications, a similar approach using a dilution series (starting with 1:10, 1:50, 1:100, 1:500) on replicate sections or cells is recommended. Include positive controls (tissues known to express RPL24 such as human placenta or HeLa cells) and negative controls (antibody diluent only) .

What is the significance of the discrepancy between calculated (18 kDa) and observed (21-23 kDa) molecular weights for RPL24?

The molecular weight discrepancy between calculated (18 kDa) and observed (21-23 kDa) values for RPL24 represents an important consideration for experimental interpretation . This difference may be attributed to:

• Post-translational modifications such as phosphorylation, ubiquitination, or SUMOylation

• Protein-protein interactions that persist during sample preparation

• Structural characteristics affecting protein migration in SDS-PAGE

Researchers should recognize this discrepancy when interpreting Western blot results and not mistakenly consider the 21-23 kDa band as non-specific. To confirm band identity in uncertain cases, additional validation through knockdown/knockout experiments is recommended. In studies examining RPL24 in cervical cancer cells, researchers have successfully used siRNA approaches to confirm antibody specificity by demonstrating band disappearance in RPL24-knockdown samples .

How should I design control experiments to validate RPL24 antibody specificity in my research model?

A comprehensive validation strategy for RPL24 antibody should include:

• Positive controls: Include samples known to express RPL24 (A549, HEK-293, or Jurkat cells for Western blot; human placenta, kidney, liver, spleen, or ovary tissue for IHC)

• Negative controls:

  • Primary antibody omission control

  • Isotype control using rabbit IgG at equivalent concentration

  • Ideally, RPL24 knockdown/knockout samples (as demonstrated in published research)

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to confirm binding specificity

• Multiple antibody verification: If possible, use a second RPL24 antibody raised against a different epitope and compare staining patterns

• Cross-technique validation: Confirm findings across multiple techniques (e.g., if protein is detected by Western blot, verify localization by IF)

In published research examining RPL24 in cervical cancer, researchers have employed both vector construction for RPL24 overexpression and RPL24 knockdown experiments to validate antibody specificity and function .

How can RPL24 antibody be used to investigate cell cycle regulation in cancer?

RPL24 has emerged as a potential regulator of cell cycle progression, particularly at the G2/M checkpoint in cancer cells. When designing experiments to investigate this relationship:

• Treatment-response studies: RPL24 expression changes can be examined following treatment with cell cycle modulators. For example, in cervical cancer cells, RPL24 expression increases after Cisplatin (CDDP) treatment, correlating with G2/M phase arrest .

• Co-immunoprecipitation: Using RPL24 antibody for pull-down experiments (recommended at 0.5-4.0 μg for 1.0-3.0 mg of protein lysate) can help identify protein-protein interactions with cell cycle regulators .

• Dual staining approaches: Combine RPL24 immunofluorescence with cell cycle markers such as CCNB1 (a mitotic M-phase marker) to correlate expression patterns with specific cell cycle phases .

• Functional validation: Complement antibody-based detection with genetic manipulation (overexpression/knockdown) to establish causal relationships between RPL24 levels and cell cycle progression.

Research has demonstrated that RPL24 protein expression significantly increases in cervical cancer cell lines after CDDP treatment, accompanied by G2/M phase cell cycle arrest, suggesting RPL24 may function as a cell cycle regulator in cancer progression .

What methodological considerations are important when using RPL24 antibody for prognostic biomarker studies in cancer?

When investigating RPL24 as a potential prognostic biomarker in cancer:

Research has established that RPL24 expression levels may have prognostic significance in cervical cancer, with overexpression studies showing reduced tumor growth rates in animal models, suggesting that low-RPL24 expression groups had poorer prognoses .

What are the critical steps for optimizing RPL24 antibody performance in immunohistochemistry?

For optimal IHC results with RPL24 antibody:

• Fixation and processing:

  • Use 10% formalin-fixed, paraffin-embedded tissues sectioned at 5μm thickness

  • Ensure sections have well-preserved morphology for accurate interpretation

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Perform time-course experiments to determine optimal retrieval duration

• Antibody incubation:

  • Start with 1:50 dilution in PBS buffer

  • Incubate at room temperature for 2 hours (as validated in published protocols)

  • Consider temperature and duration modifications based on signal intensity

• Detection system:

  • Use high-sensitivity detection kits appropriate for rabbit primary antibodies

  • Include DAB development time controls to ensure consistency

• Counterstaining and evaluation:

  • Implement standardized scoring systems

  • Have multiple independent researchers review each section to eliminate scoring errors

Published studies have successfully detected RPL24 in human placenta, kidney, liver, spleen, and ovary tissues using these parameters, with detailed evaluation of staining patterns in relation to clinical factors .

How can I troubleshoot weak or non-specific signals when using RPL24 antibody in Western blotting?

When encountering issues with Western blotting using RPL24 antibody:

For weak signals:

• Decrease antibody dilution (start at 1:5000 and adjust as needed)

• Increase protein loading (considering RPL24 is a ribosomal protein, it should be abundant)

• Extend primary antibody incubation time or switch to overnight at 4°C

• Use more sensitive detection reagents (enhanced chemiluminescence)

• Ensure proteins are efficiently transferred to membrane (particularly important for smaller proteins)

For non-specific bands:

• Increase blocking stringency (5% BSA or milk, consider adding 0.1% Tween-20)

• Increase antibody dilution (up to 1:50000 has been validated)

• Add additional wash steps with TBST

• Confirm you're looking at the correct molecular weight range (21-23 kDa for RPL24)

• Use freshly prepared samples to minimize degradation products

For high background:

• Ensure membranes are adequately blocked

• Use highly purified primary and secondary antibodies

• Consider using different blocking agents (switch between BSA and milk)

• Increase the number and duration of wash steps

Remember that RPL24 appears at 21-23 kDa rather than its calculated 18 kDa molecular weight , which is critical for accurate band identification and interpretation.

How should RPL24 antibody data be interpreted in the context of tumor response to chemotherapy?

Interpreting RPL24 expression changes in response to chemotherapy requires careful consideration of several factors:

• Temporal dynamics:

  • Establish baseline RPL24 expression before treatment

  • Monitor changes at multiple time points after treatment

  • Consider both immediate and delayed response patterns

• Correlation with cell cycle markers:

  • Analyze RPL24 expression in relation to G2/M phase markers (e.g., CCNB1)

  • Determine if changes in RPL24 precede or follow cell cycle arrest

  • Research has shown that RPL24, CCNB1, and p53 protein were simultaneously overexpressed in cervical cancer cells after Cisplatin treatment, accompanied by G2/M phase arrest

• Integration with cellular response indicators:

  • Correlate RPL24 levels with apoptotic markers

  • Assess relationship with DNA damage response proteins

  • Consider impact on cell viability and proliferation metrics

• Translational significance:

  • Compare in vitro findings with patient tumor samples before and after chemotherapy

  • Evaluate whether RPL24 levels correlate with treatment response in clinical settings

  • Research has demonstrated that overexpression of RPL24 suppresses tumor growth in vivo, suggesting potential tumor-suppressive functions

When interpreting such data, it's critical to establish whether RPL24 expression changes are causative of or reactive to treatment effects through complementary functional studies.

What statistical approaches are most appropriate for analyzing RPL24 antibody data in biomarker studies?

For robust statistical analysis of RPL24 as a potential biomarker:

When reporting statistics, include specific p-values, confidence intervals, and effect sizes rather than simply stating significance, as demonstrated in published research where p<0.05 was considered statistically significant .

How does RPL24 antibody performance compare in detecting various isoforms or post-translationally modified forms of the protein?

The standard RPL24 antibody (17082-1-AP) targets specific epitopes that may not equally detect all protein variants:

• Isoform specificity:

  • The antibody is raised against RPL24 fusion protein (Ag7085) which may have differential reactivity against splice variants

  • Researchers should verify which specific region of RPL24 the antibody targets and whether this region is conserved across known isoforms

• Post-translational modifications (PTMs):

  • The discrepancy between calculated (18 kDa) and observed (21-23 kDa) molecular weights suggests potential PTMs

  • Standard Western blotting may not distinguish between different phosphorylated states

  • For PTM-specific detection, consider:

    • Phospho-specific antibodies when available

    • Combined approaches using lambda phosphatase treatment

    • 2D gel electrophoresis to separate proteins based on both molecular weight and charge

• Experimental validation:

  • When investigating specific RPL24 forms, validate findings using:

    • Mass spectrometry for definitive protein identification and PTM mapping

    • Recombinant expression of specific variants as positive controls

    • Mutational analysis of putative modification sites

This detailed understanding of antibody specificity is crucial when interpreting changes in RPL24 detection across different experimental conditions or tissue types.

What are the methodological considerations when using RPL24 antibody in combination with other ribosomal protein antibodies for studying ribosome biogenesis?

When designing multiplex studies of ribosomal proteins:

• Antibody compatibility assessment:

  • Verify host species differences to enable simultaneous detection (RPL24 antibody is rabbit-derived)

  • Test for cross-reactivity between secondary antibodies

  • Validate epitope accessibility when multiple ribosomal proteins are in complexes

• Optimization of multi-protein detection:

  • For fluorescence microscopy:

    • Carefully select fluorophores with minimal spectral overlap

    • Establish sequential staining protocols if antibodies are from the same host species

    • Include single-stain controls to assess bleed-through

  • For Western blotting:

    • Consider molecular weight differences for simultaneous detection (RPL24 at 21-23 kDa)

    • Optimize stripping and reprobing protocols if sequential detection is required

    • Validate that stripping does not diminish target protein detection

• Functional validation approaches:

  • Complement antibody-based detection with genetic approaches:

    • Similar to RPL24 overexpression studies in cancer research

    • Coordinate knockdown/knockout of multiple ribosomal proteins

    • Use RNA profiling to correlate protein-level changes with transcriptional regulation

• Data integration strategies:

  • Implement quantitative image analysis for co-localization studies

  • Develop normalization strategies when comparing multiple ribosomal proteins

  • Consider stoichiometric relationships between different ribosomal components

These methodological considerations ensure valid interpretations when studying the complex interplay between RPL24 and other ribosomal proteins in normal and pathological states.

What quality control measures should be implemented when using RPL24 antibody across different experimental batches?

To ensure consistency and reliability across experiments:

• Reference sample inclusion:

  • Include a common positive control sample (e.g., HEK-293 or A549 cell lysate) in every experiment

  • Use this reference to normalize signal intensity across different experimental runs

  • Monitor deviation in reference sample signal as an indicator of antibody performance

• Antibody validation with each new lot:

  • Perform side-by-side comparison between old and new antibody lots

  • Document lot-specific optimal dilutions and incubation conditions

  • Consider creating a laboratory validation certificate for each new lot

• Standard curve generation:

  • For quantitative applications, prepare a dilution series of positive control lysate

  • Establish limits of detection and quantification

  • Verify linear range of signal for accurate quantitative comparison

• Storage and handling validation:

  • Test antibody performance after different storage durations at recommended conditions (-20°C)

  • Assess impact of freeze-thaw cycles on antibody performance

  • Consider preparing working aliquots to minimize repeated freeze-thaw

• Documentation practices:

  • Maintain detailed records of antibody source, lot number, dilution, and incubation conditions

  • Document any deviations from standard protocols

  • Include representative images of positive and negative controls in laboratory notebooks

Implementation of these quality control measures significantly improves data reproducibility and facilitates meaningful comparison of results across different experimental series.

How can I distinguish between true RPL24 signal and cross-reactivity with other ribosomal proteins?

Discriminating specific RPL24 signal from potential cross-reactivity requires:

• Epitope analysis:

  • Review the immunogen sequence (RPL24 fusion protein Ag7085)

  • Perform sequence alignment with other ribosomal proteins to identify regions of homology

  • Consider potential cross-reactivity based on structural similarities within the ribosomal protein family

• Validation using genetic approaches:

  • Implement RPL24 knockdown/knockout controls

  • Verify signal reduction in Western blot, IHC, or IF following RPL24 depletion

  • This approach has been successfully employed in RPL24 cancer research

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • Include both RPL24-specific peptides and peptides from potentially cross-reactive proteins

  • Observe which peptides successfully compete for antibody binding

• Mass spectrometry verification:

  • Perform immunoprecipitation using RPL24 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Identify any co-precipitating ribosomal proteins that might contribute to observed signals

• Multi-antibody approach:

  • Compare staining patterns using antibodies targeting different RPL24 epitopes

  • Consensus results across multiple antibodies increase confidence in specificity